Alestramustine
 |
|
| Identifiers | |
|---|---|
|
Systematic (IUPAC) name: [(8R,9S,13S,14S,17S)-3-[bis(2-Chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] (2S)-2-aminopropanoate
|
|
| CAS Number | 139402-18-9 |
| PubChem (CID) | 20055302 |
| ChemSpider | 16736564 |
| UNII | 81U8A51CHK |
| ChEMBL | CHEMBL2106670 |
| Chemical and physical data | |
| Formula | C26H36Cl2N2O4 |
| Molar mass | 511.48104 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Alestramustine (INN), also known as estradiol 3-(bis(2-chloroethyl)carbamate), 17-ester with L-alanine, is a nitrogen mustard alkylating antineoplastic drug that was never marketed.[1][2] It is the L-alanine ester of estramustine, which is a combination of the nitrogen mustard normustine coupled via a carbamate to the estrogen estradiol.[1][3] Alestramustine acts as a prodrug to estramustine, and also forms estradiol as a byproduct.[1][3] The drug, via its active metabolites, binds to microtubule-associated proteins and β-tubulin and interferes with microtubule function, thereby inhibiting cell division.[1][3] Due to its estrogen moiety, alestramustine is selectively concentrated in estrogen receptor-positive cells such as prostate and breast.[1]
See also[edit]
References[edit]
- ^ a b c d e NCI Thesaurus. "Alestramustine". Retrieved 24 June 2016.
- ^ G. W. A. Milne (1 July 2000). Ashgate Handbook of Antineoplastic Agents. Wiley. p. 5. ISBN 978-0-566-08382-2.
- ^ a b c KD Tripathi (30 September 2013). Essentials of Medical Pharmacology. JP Medical Ltd. pp. 866–. ISBN 978-93-5025-937-5.
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
 |
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
